New cancer drug PEP08 enters first human trials for Tough-to-Treat tumors
Disease control
Recruiting now
This is the first study in people testing PEP08, a new oral cancer drug, for patients with advanced solid tumors that have a specific genetic change called MTAP deletion. The main goals are to find safe doses, see how the body processes the drug, and look for early signs that it …
Phase: PHASE1 • Sponsor: PharmaEngine • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC